Rachel Matt

Rachel Matt has over 12 years of experience in the pharmaceutical and biotechnology industry. In 2007, they were an Undergraduate Research Assistant at the University of Montana. In 2009, they worked as a Research Scientist, Formulations/Analytical, Biologicals Manufacturing Specialist, and Research Summer Intern at GlaxoSmithKline Biologicals. In 2012, they were a Graduate Student at Stanford University School of Medicine, where they developed novel crystallization aids for membrane proteins and solved high-resolution crystal structures. Rachel also completed coursework and a team-based drug discovery project design, and received funding to pursue a peptide therapeutic for sickle cell disease. In 2014, they were a Consultant for Biotech Connection - Bay Area, Inc. In 2017, they were a Senior Scientist at Merck, where they identified and evaluated therapeutic targets for early discovery programs in skeletal muscle disease indications. In 2019, they joined CuraSen Therapeutics, Inc. as a Senior Principal Scientist, where they led a preclinical pharmacology research laboratory to support clinical programs and advance lead candidates to IND-readiness. Rachel also authored pharmacology reports for a successful IND application and designed combination dosing regimens for in vivo PET studies.

Rachel Matt received their Bachelor's degree in Chemistry, Biochemistry, and Mathematics from the University of Montana in 2009. Rachel then attended Stanford University School of Medicine, graduating with a Doctor of Philosophy (PhD) in Chemical and Systems Biology in 2017.